Blood lipids and prostate cancer: a Mendelian randomization analysis
Caroline J. Bull, Carolina Bonilla, Jeff M. P. Holly, Claire M. Perks, Neil Davies, Philip Haycock, Oriana Hoi Yun Yu, J. Brent Richards, Rosalind Eeles, Doug Easton, Zsofia Kote-Jarai, Ali Amin Al Olama, Sara Benlloch, Kenneth Muir, Graham G. Giles, Robert J. MacInnis, Fredrik Wiklund, Henrik Gronberg, Christopher A. Haiman, Johanna Schleutker, Børge G. Nordestgaard, Ruth C. Travis, David Neal, Nora Pashayan, Kay-Tee Khaw, Janet L. Stanford, William J. Blot, Stephen Thibodeau, Christiane Maier, Adam S. Kibel, Cezary Cybulski, Lisa Cannon-Albright, Hermann Brenner, Jong Park, Radka Kaneva, Jyotsna Batra, Manuel R. Teixeira, Agnieszka Micheal, Hardev Pandha, George Davey Smith, Sarah J. Lewis, Richard M. Martin and The PRACTICAL consortium
Version of Record online: 19 MAR 2016 | DOI: 10.1002/cam4.695
Using a Mendelian randomization framework, we have found some evidence to suggest an association between low-density lipoprotein and triglycerides and more clinically severe PCa, but no evidence between high-density lipoprotein and these outcomes. There is an unmet clinical need to distinguish between indolent PCas and those that will progress to impact a man's life. Our findings indicate that blood lipids may be involved in this distinction.